NFATc1-IN-1
Code | Size | Price |
---|
TAR-T61531-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T61531-10mg | 10mg | £135.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T61531-25mg | 25mg | £201.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T61531-50mg | 50mg | £269.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T61531-100mg | 100mg | £369.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T61531-500mg | 500mg | £768.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 uM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
CAS:
1912422-56-0
Molecular Weight:
375.11
Pathway:
NF-κb
Purity:
0.9964
SMILES:
O=C(NC1=CC=C(I)C=C1F)C2=CC(F)=CC=C2O
Target:
RANKL/RANK
References
Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 ; 117:70-84.
Sun J, et al. Histopathologic features of degenerative aortic valve and its mechanisms. Zhonghua Yi Xue Za Zhi. 2013 ; 93(4):280-284.